Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,392 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Pill Clear all

Conditions: Apathy, Alzheimer's Disease
Interventions: Methylphenidate, placebo, Psychosocial intervention; Drug · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Baltimore, Maryland • Charleston, South Carolina

Conditions: Alcohol Dependence, Alcoholism, Alcohol Abuse, Alcohol Use Disorder, PTSD, Posttraumatic Stress Disorder
Interventions: Topiramate, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 64 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Headache, Migraine, Migraine, Migraine Disorders, Headache
Interventions: Cognitive Behavioral Therapy (CBT), Placebo, Amitriptyline, Biofeedback-Assisted Relaxation Training (BART), Cognitive Reappraisal Training (CR); Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
Interventions: Varenicline, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 10
States / cities: Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more

Conditions: Idiopathic Peripheral Neuropathy
Interventions: Milnacipran, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Aortic Stenosis
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cannabis Dependence
Interventions: PF-04457845, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Painful Neuropathy
Interventions: Sulfasalazine, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension
Interventions: Macitentan 10mg, Placebo sugar pill; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 50
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Chronic Kidney Disease, Kidney Transplantation
Interventions: Doxercalciferol, placebo, 25-OH Vitamin D3; Drug
Lead sponsor: Mariana Markell; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Fibromyalgia
Interventions: CBT and milnacipran, CBT with a placebo, Educational with milnacipran; Other · Behavioral · Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bipolar Disorder, Cocaine Dependence
Interventions: Citicoline, Placebo, Cognitive Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Nutriceutical formulation, Placebo; Dietary Supplement · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 40 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more

Conditions: Dysfunctional Uterine Bleeding
Interventions: Medroxyprogesterone 17-Acetate; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis (CF)
Interventions: Loestrin (norethindrone acetate and ethinyl estradiol); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Parkinson's Disease
Interventions: Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID; Drug
Lead sponsor: Biotie Therapies Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more

Conditions: Rheumatoid Arthritis
Interventions: Health Log; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Erectile Dysfunction
Interventions: moxifloxacin, avanafil, sugar pill; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Tardive Dyskinesia
Interventions: SD-809, Placebo; Drug
Lead sponsor: Auspex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 32
States / cities: Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 29 more

Conditions: Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder, Alcohol Use Disorder
Interventions: aprepitant, Placebo, Manual-guided behavioral counseling; Drug · Behavioral
Lead sponsor: The Scripps Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Pemafibrate, Placebo; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 69
States / cities: Phoenix, Arizona • Campbell, California • Glendale, California + 52 more

Conditions: Type1 Diabetes
Interventions: HCL, verapamil 120mg tablet, non-HCL, placebo; Device · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Multiple Sclerosis
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: Brown, Theodore R., M.D., MPH; Individual
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Parkinson's Disease, Freezing of Gait, Cognitive Ability, General
Interventions: Droxidopa, sugar pill; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 30 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • West Bloomfield, Michigan

Search by objective public record fields.

Apathy in Dementia Methylphenidate Trial (ADMET)

Topiramate for Alcohol Use in Posttraumatic Stress Disorder

Mind and Body Approaches to Pain Reduction in Youth With Migraine

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Study of Sulfasalazine in Treating Painful Neuropathy

Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation

Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients

Drug and Talk Therapy for Fibromyalgia

Citicoline for Bipolar 1 Disorder and Cocaine Dependence

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

Gender Disparity and Hormones in Cystic Fibrosis

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

The Health Log: A Randomized Clinical Trial

A Thorough EKG Safety Study of TA-1790 (Avanafil)

Aim to Reduce Movements in Tardive Dyskinesia

Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence

PROMINENT-Eye Ancillary Study (Protocol AD)

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

A Study to Test the Use of Duloxetine for Pain in MS

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease